More recently, additional 211At‐labeled PSMA inhibitors have been developed, such as [211At]8‐Ga (Figure 13), which exhibited excellent in vivo biodistribution, characterized by high tumor uptake, rapid renal clearance, and low kidney retention. This evidence concerns the gene FOLH1 and neoplasm.